Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (0HI3:LSE) closed at 18.25, 88.08% above the 52 week low of 9.70 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 18.25 |
Low | 18.25 |
Bid | -- |
Offer | -- |
Previous close | 18.97 |
Average volume | 2.06k |
---|---|
Shares outstanding | 138.10m |
Free float | 118.88m |
P/E (TTM) | -- |
Market cap | 2.60bn USD |
EPS (TTM) | -1.38 USD |
Data delayed at least 20 minutes, as of Jul 11 2025 17:45 BST.
More ▼
Press releases
- Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
- Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
- Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
- Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
- Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
- Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
More ▼